Ability Pharmaceuticals SL:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Ability Pharmaceuticals SL - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11206
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:18
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スペイン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥33,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥67,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥101,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Ability Pharmaceuticals SL (Ability Pharma), formerly AB Therapeutics SL is a biopharmaceutical company that discovers and develops human therapeutics for the treatment of cancer and other indications. The company’s lead pipeline drug candidate includes ABTL0812, a new drug class of small molecules, developed for the treatment of lung and endometrial cancer. Ability Pharma’s pipeline also includes programs for other indications such as hematological cancers. The company offers treatment for lung, pancreatic and gynecological cancers. The company works in partnership with academic institutions to develop new drug candidates up to clinical proof of concept and later out-license them to pharmaceutical companies for development and marketing. Ability Pharma is headquartered in Barcelona, Spain.

Ability Pharmaceuticals SL – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Ability Pharmaceuticals SL, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Ability Pharmaceuticals SL, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Ability Pharmaceuticals SL, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Ability Pharmaceuticals SL, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Ability Pharmaceuticals SL, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Ability Pharmaceuticals SL, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Ability Pharma to Raise USD10.98 Million in Series A Financing 10
Ability Pharma Raises US$1.3 Million In Second Round Of Financing 11
Licensing Agreements 12
SciClone Pharma Enters into Licensing Agreement with Ability Pharma 12
Ability Pharmaceuticals SL – Key Competitors 13
Ability Pharmaceuticals SL – Key Employees 14
Ability Pharmaceuticals SL – Locations And Subsidiaries 15
Head Office 15
Recent Developments 16
Product News 16
10/05/2017: Ability Pharmaceuticals announces the approval from the French Medicines Agency ANSM to initiate a Phase 1/2a Clinical Trial with ABTL0812 to treat patients with endometrial cancer or squamous lung cancer as first-line therapy in France 16
Product Approvals 17
Sep 18, 2017: Ability Pharmaceuticals Announces EMA-Orphan Drug Designation for ABTL0812 in Pancreatic Cancer 17
Appendix 18
Methodology 18
About GlobalData 18
Contact Us 18
Disclaimer 18

List of Tables
Ability Pharmaceuticals SL, Pharmaceuticals & Healthcare, Key Facts 2
Ability Pharmaceuticals SL, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Ability Pharmaceuticals SL, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Ability Pharmaceuticals SL, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Ability Pharmaceuticals SL, Deals By Therapy Area, 2012 to YTD 2018 8
Ability Pharmaceuticals SL, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Ability Pharma to Raise USD10.98 Million in Series A Financing 10
Ability Pharma Raises US$1.3 Million In Second Round Of Financing 11
SciClone Pharma Enters into Licensing Agreement with Ability Pharma 12
Ability Pharmaceuticals SL, Key Competitors 13
Ability Pharmaceuticals SL, Key Employees 14

List of Figures
Ability Pharmaceuticals SL, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Ability Pharmaceuticals SL, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Ability Pharmaceuticals SL, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Ability Pharmaceuticals SL, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Ability Pharmaceuticals SL, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Ability Pharmaceuticals SL, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Ability Pharmaceuticals SL, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Ability Pharmaceuticals SL, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Ability Pharmaceuticals SL:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Faroe Petroleum Plc (FPM):石油・ガス:M&Aディール及び事業提携情報
    Summary Faroe Petroleum Plc (Faroe Petroleum) is an oil and gas company that concentrates on exploration, appraisal, development and production opportunities. The company has its exploration and development assets in the UK. Its operations portfolio consists of exploration, appraisal, development an …
  • Verizon Communications Inc (VZ):電力:M&Aディール及び事業提携情報
    Summary Verizon Communications Inc. (Verizon) provides communications, information and entertainment products and services. The company offers a comprehensive range of voice, data and video services and solutions through its wireless and wireline networks. Its multimedia offerings include music, vid …
  • Omega Pharma NV-製薬・医療分野:企業M&A・提携分析
    Summary Omega Pharma NV (Omega Pharma), a subsidiary of Perrigo Company plc, is a pharmaceutical company focusing on the development, manufacture and sale of prescription-free or Over the Counter (OTC) health and personal care products. The company's product portfolio includes cough and cold product …
  • At Home Group Inc. (HOME):企業の財務・戦略的SWOT分析
    At Home Group Inc. (HOME) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • DSM Dyneema BV:企業の戦略的SWOT分析
    DSM Dyneema BV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • World Fuel Services Corp (INT):企業の財務・戦略的SWOT分析
    World Fuel Services Corp (INT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Kone Corporation:企業の戦略・SWOT・財務分析
    Kone Corporation - Strategy, SWOT and Corporate Finance Report Summary Kone Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Walchandnagar Industries Ltd:企業の戦略・SWOT・財務情報
    Walchandnagar Industries Ltd - Strategy, SWOT and Corporate Finance Report Summary Walchandnagar Industries Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Dechra Pharmaceuticals Plc (DPH):企業の財務・戦略的SWOT分析
    Summary Dechra Pharmaceuticals Plc (Dechra) is a manufacturer and distributor of veterinary pharmaceutical products. The company's product portfolio includes vetoryl, felimazole, thyforon, malaseb, canaural, isaderm, cardisure, comfortan, soludox, methoxasol, cyclospray and octacillin, among others. …
  • sanofi-aventis US LLC-製薬・医療分野:企業M&A・提携分析
    Summary Sanofi-Aventis US LLC (Sanofi US), a subsidiary of Sanofi is a drug company that discovers, develops and distributes various therapeutic solutions. The company provides prescription products, vaccines and other products. Sanofi US’s vaccines include ActHIB, Adacel, DAPTACEL, Decavac, Fluzone …
  • Terumo Corporation:企業のM&A・事業提携・投資動向
    Terumo Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Terumo Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • Modern Times Group MTG AB:企業の戦略・SWOT・財務情報
    Modern Times Group MTG AB - Strategy, SWOT and Corporate Finance Report Summary Modern Times Group MTG AB - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Loews Corporation:戦略・SWOT・企業財務分析
    Loews Corporation - Strategy, SWOT and Corporate Finance Report Summary Loews Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • South Broward Hospital District:企業の戦略的SWOT分析
    South Broward Hospital District - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Rosinter Restaurants Holding Ojsc
    Rosinter Restaurants Holding Ojsc - Strategy, SWOT and Corporate Finance Report Summary Rosinter Restaurants Holding Ojsc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Jun Yang Financial Holdings Ltd:企業のM&A・事業提携・投資動向
    Jun Yang Financial Holdings Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Jun Yang Financial Holdings Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers …
  • NGM Biopharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析
    Summary NGM Biopharmaceuticals Inc (NGM Bio) is a clinical stage biopharmaceutical company which focuses on the development of drug discovery platform to generate biologic drug candidates to treat cardio-metabolic, immuno-oncology and liver diseases. Its product pipeline includes NGM282, NGM386, NGM …
  • CVS Health Corp (CVS):企業の財務・戦略的SWOT分析
    CVS Health Corp (CVS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Abdullah Al-Othaim Markets Co.:企業の戦略・SWOT・財務分析
    Abdullah Al-Othaim Markets Co. - Strategy, SWOT and Corporate Finance Report Summary Abdullah Al-Othaim Markets Co. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Barracuda Networks, Inc.:企業の戦略・SWOT・財務情報
    Barracuda Networks, Inc. - Strategy, SWOT and Corporate Finance Report Summary Barracuda Networks, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆